Vistagen Therapeutics, Inc. (VTGN)
0.2434
+0.01
(+3.35%)
USD |
NASDAQ |
Sep 10, 16:00
0.2434
0.00 (0.00%)
After-Hours: 16:00
Vistagen Therapeutics Gross Profit Margin (Quarterly) : 86.65% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.65% |
| March 31, 2026 | 59.14% |
| December 31, 2025 | 37.62% |
| September 30, 2025 | 28.29% |
| June 30, 2025 | 30.74% |
| December 31, 2024 | 31.20% |
| September 30, 2024 | 14.21% |
| June 30, 2024 | -79.76% |
| March 31, 2024 | 25.75% |
| December 31, 2023 | 65.19% |
| September 30, 2023 | 49.48% |
| June 30, 2023 | -91.44% |
| March 31, 2023 | 12.53% |
| December 31, 2022 | 26.39% |
| September 30, 2022 | |
| June 30, 2022 | 48.92% |
| March 31, 2022 | -251.0% |
| December 31, 2021 | 78.40% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | |
| March 31, 2020 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 99.07% |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -144.5% |
| Return on Assets | -113.0% |
| Return on Invested Capital | -140.0% |
| Profit Margin (Quarterly) | -882.8% |
| Operating Margin (Quarterly) | -904.3% |
| Return on Net Operating Assets | -4.83K% |